Andrew Booth, Chief Financial Officer of AbCellera Biologics Inc., has disclosed several significant transactions involving common shares in a recent SEC filing. The report, dated November 16, 2026, reveals Booth's ongoing commitment to the company through various share acquisitions and a charitable donation.

Booth's transactions are particularly noteworthy as they may indicate his confidence in AbCellera's future prospects. The pharmaceutical industry, where the company operates, often sees executives making similar moves to align their interests with those of shareholders.

Background

AbCellera Biologics Inc. is a company focused on the development of innovative therapies in the pharmaceutical sector. The firm is categorized under the SIC code for Pharmaceutical Preparations. Recent filings from AbCellera include multiple Form 4 submissions, with the latest being on November 16, 2026, and prior filings on November 13, 2026, and August 14, 2026.

What the Filing Says

The SEC filing reveals that on November 13, 2026, Booth acquired 50,000 common shares at a price of $0.3216 each. Additionally, he donated another 50,000 shares on the same day. Following these transactions, Booth holds a total of 5,413,400 shares directly and an additional 130,959 shares indirectly owned through his spouse.

Impact

These transactions may influence investor sentiment towards AbCellera, as they demonstrate Booth's personal investment in the company's success. Other executives and stakeholders may also take note of this trend, potentially leading to similar actions within the pharmaceutical industry.

What's Next

The filing does not specify what happens next regarding Booth's ongoing shareholdings or future transactions.